Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stopping Schizophrenia Before It Starts?

29.01.2010
New TAU study shows early intervention could prevent mind altering disorder

The onset of schizophrenia is not easy to predict. Although it is associated with as many as 14 genes in the human genome, the prior presence of schizophrenia in the family is not enough to determine whether one will succumb to the mind-altering condition. The disease also has a significant environmental link.

According to Prof. Ina Weiner of Tel Aviv University’s Department of Psychology, the developmental disorder, which usually manifests in early adulthood, can be triggered in the womb by an infection. But unlike developmental disorders such as autism, it takes many years for the symptoms of schizophrenia to develop.

"Pharmacological treatments for schizophrenia remain unsatisfactory, so clinicians and researchers like myself have started to dig in another direction," says Prof. Weiner. "The big question asked in recent years is if schizophrenia can be prevented."

Revolutionizing the treatment

In their study, recently reported in Biological Psychiatry, Prof. Weiner and her colleagues Dr. Yael Piontkewiz and Dr. Yaniv Assaf sought to discover biological cues that would help trace the progression of the disease before symptoms manifested. "If progressive brain changes occur as schizophrenia is emerging, it is possible that these changes could be prevented by early intervention," she says. "That would revolutionize the treatment of the disorder.

"We wondered if we could use neuro-imaging to track any early-onset changes in the brains of laboratory animals," Prof. Weiner says. "If so, could these changes and their accompanying schizophrenia-like symptoms be prevented if caught early enough?"

Beyond a doubt

Prof. Weiner and her team gave pregnant rats a viral mimic known to induce a schizophrenia-like behavioral disorder in the offspring. This method simulates maternal infection in pregnancy, a well known risk factor for schizophrenia. Prof. Weiner demonstrated that the rat offspring were normal at birth and during adolescence. But in early adulthood, the animals, like their human counterparts, began to show schizophrenia-like symptoms.

Looking at brain scans and behavior, Prof. Weiner found abnormally developing lateral ventricles and the hippocampus in those rats with "schizophrenia." Those that were at high risk for the condition could be given drugs to treat their brains, she determined. Following treatment with risperidone and clozapine, two commonly used drugs to treat schizophrenia, brain scans showed that the lateral ventricles and the hippocampus retained a healthy size.

"Clinicians have suspected that these drugs can be used to prevent the onset of schizophrenia, but this is the first demonstration that such a treatment can arrest the development of brain deterioration," says Prof. Weiner. She says that the drugs work best when delivered during the rats' "adolescent" period, several months before they reached full maturity.

Now, anti-psychotics are prescribed only when symptoms are present. Prof. Weiner believes that an effective non-invasive prediction method (looking at the developmental trajectory of specific changes in the brain), coupled with a low dose drug taken during adolescence, could stave off schizophrenia in those most at risk.

More research is needed to see at what point changes in the brain can be detected, work that Prof. Weiner has already begun. She adds that the neuroimaging was performed in the Alfredo Federico Strauss Center for Computational Neuro-Imaging, Raymond and Beverly Sackler Center for Biophysics, Tel Aviv University.

George Hunka | EurekAlert!
Further information:
http://www.aftau.org

More articles from Health and Medicine:

nachricht 'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton

nachricht A new approach to high insulin levels
18.09.2017 | Schweizerischer Nationalfonds SNF

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

New quantum phenomena in graphene superlattices

19.09.2017 | Physics and Astronomy

A simple additive to improve film quality

19.09.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>